Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997638 | 0.78 | POLB (0.32) | BLMPMP22HSD17B10 | |
| SCHEMBL14201301 | 0.74 | KCNQ3 (0.39) | — | |
| SCHEMBL22932547 | 0.74 | BLM (0.42) | BLMPMP22HSD17B10SMN1; SMN2 | |
| SCHEMBL24784667 | 0.72 | BLM (0.48) | BLMPMP22HSD17B10SMN1; SMN2 | |
| SCHEMBL29638790 | 0.72 | BLM (0.48) | BLMPMP22HSD17B10SMN1; SMN2 | |
| SCHEMBL23766092 | 0.72 | CA14 (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL23765896 | 0.72 | CA14 (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL13173708 | 0.71 | BLM (0.40) | BLMPMP22HSD17B10 | |
| SCHEMBL6664456 | 0.71 | HSD17B10 (0.46) | BLMPMP22HSD17B10SMN1; SMN2 | |
| SCHEMBL81956 | 0.71 | HSD17B10 (0.46) | BLMPMP22HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | BLM 4257/4885PMP22 4128/4885HSD17B10 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.